DE3373272D1 - Sustained release diethylpropion compositions - Google Patents

Sustained release diethylpropion compositions

Info

Publication number
DE3373272D1
DE3373272D1 DE8383104832T DE3373272T DE3373272D1 DE 3373272 D1 DE3373272 D1 DE 3373272D1 DE 8383104832 T DE8383104832 T DE 8383104832T DE 3373272 T DE3373272 T DE 3373272T DE 3373272 D1 DE3373272 D1 DE 3373272D1
Authority
DE
Germany
Prior art keywords
sustained release
diethylpropion
compositions
capsules
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383104832T
Other languages
English (en)
Inventor
Eugene L Walters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE3373272D1 publication Critical patent/DE3373272D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
DE8383104832T 1982-05-20 1983-05-17 Sustained release diethylpropion compositions Expired DE3373272D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/379,848 US4421736A (en) 1982-05-20 1982-05-20 Sustained release diethylpropion compositions

Publications (1)

Publication Number Publication Date
DE3373272D1 true DE3373272D1 (en) 1987-10-08

Family

ID=23498964

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8383104832T Expired DE3373272D1 (en) 1982-05-20 1983-05-17 Sustained release diethylpropion compositions

Country Status (11)

Country Link
US (1) US4421736A (de)
EP (1) EP0095123B1 (de)
JP (1) JPS58210008A (de)
AT (1) ATE29215T1 (de)
AU (1) AU550992B2 (de)
DE (1) DE3373272D1 (de)
IE (1) IE55115B1 (de)
IL (1) IL68703A (de)
NZ (1) NZ204263A (de)
PH (1) PH19295A (de)
ZA (1) ZA833489B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
NL8600161A (nl) * 1985-02-05 1986-09-01 Sandoz Ag Farmaceutische preparaten die 9,10-dihydroergotalkaloiden bevatten.
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
FR2745500B1 (fr) * 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US6833140B2 (en) * 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (de) * 2001-06-11 2004-09-29 Xenoport Inc Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
JP2006522146A (ja) * 2003-03-31 2006-09-28 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防
EP2354120A1 (de) 2003-08-20 2011-08-10 XenoPort, Inc. Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
MXPA06002731A (es) * 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
MXPA06003043A (es) * 2003-09-17 2006-05-31 Xenoport Inc Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba.
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
CN101068538A (zh) * 2004-11-04 2007-11-07 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
ZA200800311B (en) * 2005-06-20 2009-04-29 Xenoport Inc Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
WO2007140272A2 (en) 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
CN103228142A (zh) 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3595663A4 (de) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. Mehrfachuntereinheit-opioid-prodrugs mit resistenz gegen überdosierung und missbrauch
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
KR20210013081A (ko) 2018-05-14 2021-02-03 엑스진 파마슈티컬 인크. 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL101341C (de) * 1957-04-17
US3001910A (en) * 1958-04-16 1961-09-26 Temmler Werke Anorexigenic propiophenones
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3150043A (en) * 1961-02-23 1964-09-22 Orsymonde Anorectic composition
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
BE640616A (de) * 1962-12-19
NL297631A (de) * 1963-06-03
US3297804A (en) * 1964-05-19 1967-01-10 Ono Pharmaceutical Co Method of filling hard capsules with granules by the open-mouth-down punching method
CH415963A (de) * 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3427378A (en) * 1965-02-12 1969-02-11 American Cyanamid Co Sustained release encapsulated formula
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
NL6808619A (de) * 1968-06-19 1969-12-23
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
ZA765931B (en) * 1975-10-10 1977-09-28 Squibb & Sons Inc Controlled release tablet
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules

Also Published As

Publication number Publication date
AU550992B2 (en) 1986-04-10
IE831172L (en) 1983-11-20
EP0095123A2 (de) 1983-11-30
NZ204263A (en) 1986-02-21
JPS58210008A (ja) 1983-12-07
US4421736A (en) 1983-12-20
IL68703A (en) 1986-09-30
EP0095123B1 (de) 1987-09-02
IL68703A0 (en) 1983-09-30
ZA833489B (en) 1984-02-29
IE55115B1 (en) 1990-06-06
AU1461783A (en) 1983-11-24
EP0095123A3 (en) 1984-12-12
ATE29215T1 (de) 1987-09-15
PH19295A (en) 1986-03-05

Similar Documents

Publication Publication Date Title
DE3373272D1 (en) Sustained release diethylpropion compositions
GB2117239B (en) Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
IL112637A0 (en) A pharmaceutical composition containing oxybutynin and methods for the preparation thereof
ES519423A0 (es) Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos.
GB2056278B (en) Sustained release compositions
IL58279A0 (en) Sustained release pharmaceutical compositions
IL67497A (en) Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
IT8322616A0 (it) Composizione per agenti antitumorali.
EP0608780A3 (de) Fluorosiloxantrennmittelzusammensetzungen.
EP0114878A4 (de) Phthalazin substituierte aminomethylbenzolabkömmlinge, zusammensetzungen und verwendung.
DE3887839T2 (de) Trennmittelzusammensetzung.
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
AU8111282A (en) 1,2,3,6 tetrahydropyridines as anorectic agents
IL69599A0 (en) Tert.-butanol derivatives,their preparation and antimycotic agents containing them
ZA804421B (en) Substituted-1,2,3-thiadiazole-safening agents
DE3278126D1 (en) Sustained release compositions
AP2000001746A0 (en) Anti- first-pass effect compounds.
AU4015778A (en) 2',6'-dihydroxy-9-(2,5-dihydroxy-9-(2,5-dihydroxypeny)-octylpheneone as an anti-oxidant
JPS5250481A (en) Air cylinder
IT8220526A0 (it) Composizioni acaricide.
ES532108A0 (es) Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos.
DE3360323D1 (en) Trimethylbicyclo(4.3.0)non-1-ene derivatives, their preparation and use as perfumes, and the perfumed compositions containing them
DE3366925D1 (en) Physiologically active pterocarpan compounds, methods for the isolation thereof and therapeutically active compositions containing them

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERRELL PHARMACEUTICALS INC. (N.D.GES.D. STAATES D